r/wallstreetbets
大轮动：资金正逃离AI套牢盘，摇摇晃晃地涌入减肥药
资金正从AI股票轮动至医疗保健板块，特别是NVO和LLY等GLP-1减肥药。
- 随着AI资本开支回报率受到质疑，宏观资金正从AI/科技股轮动至防御性板块。
- GLP-1市场正通过新的口服制剂不断扩张，吸引了大量新患者。
- 减肥药领域具有强劲的基本面增长和市场主导地位。
- AI交易逻辑动摇，科技板块正经历连续下跌。
- GLP-1公司面临未来指引中潜在的销售额下降风险。
好了，各位，聚一聚。这周除了我的看跌期权到期归零外，还真发生点事儿。
情况是这样的：纳斯达克刚刚创下连续第五个下跌日。所谓的AI无限印钞漏洞交易开始摇摇欲坠。据传OpenAI正在考虑将IPO推迟到明年，突然间所有人都想起来——‘花5000亿美元买GPU，再慢慢想收入’这个计划可能根本行不通。芯片股被狠狠砸了一顿，苹果和微软也在自家的麻烦里自顾不暇，双双亏损。
那么聪明钱跑哪儿去了？防御性板块。而医疗保健尤其受到热捧，成为本周表现第二好的行业，等权重指数上涨，说明不再只是那七家巨无霸在撑盘了。这就是轮动发生前的样子，还没明显到让人一眼看穿。
登场：瘦身夏日身体联盟。 💊
诺和诺德（NVO） 是这里典型的困境价值股。股价此前被砸得体无完肤，仿佛欠了谁钱一样，从2024年高点已下跌约65%，3月因CagriSema临床数据不及预期及两次指引下调，最大回撤超过50%。但行情似乎正在转向：
• 口服版Wegovy将于7月6日在英国上市。这是欧洲首个获批的GLP-1减重口服药。
• 据报道，仅Chemist4U一家就有超过1万名排队等待名单，其中约75%的人从未使用过任何GLP-1药物。这可不是抢Lilly的客户，而是在把整个蛋糕做大。
• 欧盟五月已给出积极监管意见，欧盟委员会批准待定，德国、丹麦、英国将于6月7日陆续上市。已经开始了。
• 在获得英国批准后股价反弹约6%，周五收盘收红，而科技股则一片惨绿。
礼来（LLY） 依然是那个800磅的大猩猩，别搞错了。Mounjaro加Zepbound去年贡献了约360亿美元收入，礼来预计今年增长约28%，而诺和诺德却指引下滑。他们的口服药Foundayo因为是新分子/新品牌，推广速度较慢，而orforglipron则是未知数。如果你要的是优质成长股，选LLY；要是想搏一个被低估的反转彩票，那就投NVO。
空头逻辑（因为我不是全然脑残）：诺和诺德自己对2026年的指引是销售额下降4%至12%。美国定价持续承压，礼来正在抢份额。分析师普遍持观望态度（比如5家买入、9家持有，0家卖出，也就是‘我们真不知道’）。口服药需求确实存在，但真正关键的指标是：人们能否坚持用到剂量爬坡完成。
催化剂：诺和诺德8月5日发布二季度财报。口服药留存率数据将决定它是起飞还是终结。
总结：AI泡沫正在漏气，资金转向防御，医疗板块受追捧，而GLP-1口服药大战正走向全球。NVO = 反转搏命赌局，LLY = 相对安全的稳妥选择。
持仓：两边都买了，因为我拒绝在刀尖上选边站。NFA，我吃蜡笔。 🖍️🐂
No way bro used AI to make a post about money leaving AI
"You are absolutely right"
"This is an exceptionally sharp analysis"
Llms are never wrong and Claude told me it’s safe to drink peroxide to cleanse my body
AI slop. No convictions, paper hands, changes mind like they’re the front runner to an old Katy Perry song.
Puts? Worthless
Bear thesis? Liquidated
Long term outlook? “Just buy this pharmaceutical company bro I swear they’re gonna pass FDA trials.”
I finally pulled the trigger. After watching my tech portfolio get absolutely hammered while I sat there holding bags of "AI-integrated" garbage, I decided enough was enough. I spent the better part of the weekend drowning in clinical trial data and European supply chain projections, convinced that if I could just time the GLP-1 transition right, I could finally climb out of the hole. I was deep in the zone, spreadsheets open, running sensitivity analysis on the Q2 guidance until my eyes were burning.
Just as I was about to execute the trade, there was a knock at the door. I opened it to see this little old lady in a dusty coat. She started rambling about pharmaceutical patent expiration dates and global distribution bottlenecks in a way that sounded strangely informed. Intrigued, I invited her in to take a look at my due diligence, thinking maybe she actually knew something. She walked over, stared at my terminal for a long moment, then tilted her head and said, "I have the inside track on the Q2 earnings call, but it’s gonna cost you about tree fiddy."
I took a good hard look at her, squinting as she seemed to grow about 500 feet taller right there in my living room. It wasn’t a grandmother! it was that goddamn Loch Ness Monster! I yelled, "Dammit, Loch Ness Monster, get out of my house! I ain't givin' you no tree fiddy!"
Your post? Yeah...
Just put the fries in the bag my mouth
https://preview.redd.it/7axmiggb7s9h1.png?width=1024&format=png&auto=webp&s=e7824775d318764def583dc8d3409e686c88c1ed
I quit drinking a month ago, my hands shake from 0DTEs now not liquor
Funny diamond hands dont shake they hold
GLP-1 pricing is a race to the bottom.
Disagree.
The stuff coming out in 2028 is crazy shit. I’m on one now for alcohol reduction and it’s changed my life.
Not to mention. How stupid fit i am getting
I'm glad that it's working out for you, but the reasons that the prices are falling do not indict the efficacy of the product.
People would literally rather inject gray market peptides from China than pay these companies.
Anything is better than moderate physical activity and making better food choices when insurance won't cover the drugs.